First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

STRIDE treatment shows a 14.4% objective response rate and a 19.8% incidence of Grade 3/4 PRAEs within 6 months in poor-prognosis unresectable hepatocellular carcinoma patients.

• Why it matters: Patients with poor prognostic factors are often excluded from clinical trials, leaving a gap in evidence for effective treatments in this high-need group. Understanding safety and efficacy in these populations is crucial for improving outcomes.
• What they did: The phase IIIb SIERRA study enrolled 111 adults with uHCC with Child-Pugh B7/B8, ECOG PS 2, or Vp4, and assessed safety and response to STRIDE (tremelimumab plus durvalumab) until disease progression, toxicity, or withdrawal.
• The result: Findings suggest a favorable risk-benefit profile for STRIDE in this population, with safety and efficacy data supporting its use in previously underrepresented patients with poor prognosis.